Applied Clinical Trials
December 01, 2015
Issue PDF
22
5
Subject Recruitment: The Ideas Initiative Trial Design: Early Phase CNS Drug Liabilities; Improving Enrollment Forecasts Also in this issue: Update on Europe's Clinical Trial Rules Debate Public Perception of Clinical Research Clinical Trial Barriers
May 01, 2013
Data Anlaysis
22
5
Medidata Solutions
May 01, 2013
Feature Article
22
5
Improving diversity, education, and advancement in studies: a look at the IDEAS initiative.
May 01, 2013
News
22
5
The Avoca Group's "2012 Industry Survey," sponsors and service providers were asked to share their experiences with strategic partnerships.
May 01, 2013
Oncology Clinical Trials
22
5
Oncology clinical trials: A case for Russia and Eastern Europe.
May 01, 2013
22
5
Medidata Solutions
May 01, 2013
Feature Article
22
5
A useful tool for clinical research professionals to estimate potential recruitment duration.
May 01, 2013
A Closing Thought
22
5
The statistics show that fewer and fewer physicians are willing to take part in trials and that around half of those that do so once never do so again.
May 01, 2013
Feature Article
22
5
Only eight percent of CNS drugs will reach approval, in part because of the high adverse effects standards.
May 01, 2013
Business News
22
5
Industry news focusing on the people and organizations who work in the clinical trials profession.
May 01, 2013
View from Brussels
22
5
Debate rages on, European Parliament set to decide on new clinical trial rules in late October.
May 01, 2013
Oncology Clinical Trials
22
5
Accelerating the discovery and delivery of personalized medicine.
May 01, 2013
CTI Insights
22
5
Public's view of clinical research has improved during the past five years, CISCRP survey reveals.
May 01, 2013
News
22
5
There is great optimism that new genomic discoveries and technical advances will reduce the cost and time of moving important new therapies for cancer and other critical diseases from laboratory to patients.
May 01, 2013
News
22
5
Workers from France, Italy, and Spain account for more than a third of total staff at the European Medicines Agency, plus around 68% of agency staff members are women, according to new statistics.
May 01, 2013
Oncology Clinical Trials
22
5
Increasing development costs and high failure rates require earlier integration of imaging data in the Phase I setting.
May 01, 2013
Issue PDF
22
5